EXO 050
Alternative Names: EXO-050Latest Information Update: 25 Jun 2021
Price :
$50 *
At a glance
- Originator Coya Therapeutics
- Class Antidementias; Exosome therapies; Proteins; RNA
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Frontotemporal dementia
Most Recent Events
- 02 Jun 2021 Coya Therapeutics has patents pending for exosome platforms as of June 2021 (Coya Therapeutics website, June 2021)
- 02 Jun 2021 Preclinical trials in Frontotemporal dementia in USA (Parenteral) (Coya Therapeutics pipeline, June 2021)
- 02 Jun 2021 Coya Therapeutics plans a first-in-human trial for Neurodegenerative Disorders beginning end of 2021 and/or 2022 (Coya Therapeutics website, June 2021).